Gilead Sciences Inc

GILD

Company Profile

  • Business description

    Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

  • Contact

    333 Lakeside Drive
    Foster CityCA94404
    USA

    T: +1 650 574-3000

    E: [email protected]

    https://www.gilead.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    17,600

Gilead Sciences Inc News & Analysis

stocks

10 cheap wide-moat US stocks for 2025

Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance

US stock market outlook: tariffs are 2025's wild card

Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks

10 cheap US dividend-growth stocks to buy

The stocks of these companies with a history of dividend increases look undervalued today.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,245.0066.30-0.71%
CAC 407,843.04126.65-1.59%
DAX 4024,273.1289.97-0.37%
Dow JONES (US)45,388.41243.33-0.53%
FTSE 1009,321.4012.200.13%
HKSE25,829.91490.771.94%
NASDAQ21,537.1640.630.19%
Nikkei 22542,807.82174.530.41%
NZX 50 Index13,079.5036.740.28%
S&P 5006,460.266.65-0.10%
S&P/ASX 2008,972.4071.70-0.79%
SSE Composite Index3,883.5657.801.51%

Market Movers